The Neurobiology and Brain Tumor Program (NBTP) brings together world leading neuroscientists, cancer biologists and physicians within a highly interactive group. The overall goal of the Program is to develop curative, minimally toxic therapies, for children with brain tumors. The Program includes 30 Full Members and 4 Associate (junior mentored) Members, drawn from 9 academic departments. The members are organized into three focus groups that contribute thematic, complementary expertise to a programmatic pipeline that is translating basic neuroscience discoveries to the clinic: (i) Fundamental Neuroscience: this group studies the development, function, and death of normal and neoplastic neural tissues. The research in this group has been greatly facilitated by an NCI-P01 Program Project Grant held for over 9 years Leveraging core expertise in human and mouse genetics, this group also generates new mouse models of childhood brain tumors for biology studies and therapeutic discovery, (ii) Translational Research: this group facilitates direct collaborations between the Fundamental Neuroscience and Brain Tumor Therapy Groups, translating the results of genomic studies into robust, diagnostic tests of tumor subtype; developing new disease risk stratification tools; and employing the mouse models generated in the Program to identify potential new treatments of brain tumors, (iii) Brain Tumor Therapy: this group translates the discoveries made within groups (i) and (ii) to clinical trial. Members also study the late effects of brain tumor therapies and how to mitigate these. Clinical and laboratory-based experts work closely together to design and implement cutting-edge clinical trials that include appropriate molecular and pharmacokinetic assays. Members also play leading and collaborative roles in the national consortia, including the Children's Oncology Group and Pediatric Brain Tumor Consortium. The NBTP relies heavily upon the outstanding Shared Resources provided by the Center and close collaborative links with the other Programs. The NBTP membership is supported by $12.0 million In cancer-related funding ($7.8 million peer-reviewed; $4.2 million other sources). Program members published over 431 manuscripts during the last funding period, 28% of which were intra-programmatic collaborations and 34% of which were inter-programmatic.

Public Health Relevance

Brain tumors remain a leading cause of death among children diagnosed with cancer. There is a great need for new, less toxic treatments, since cure rates have remained static for more than a decade, and survivors suffer debilitating side effects. The NBTP, together with the unique resources and collaborations available in the Cancer Center, are working to develop effective and relatively none toxic therapies for these devastating childhood cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-39
Application #
9439723
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Shadrick, William R; Slavish, Peter J; Chai, Sergio C et al. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26:25-36
Ramsey, Laura B; Balis, Frank M; O'Brien, Maureen M et al. (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23:52-61
Churchman, Michelle L; Qian, Maoxiang; Te Kronnie, Geertruy et al. (2018) Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell 33:937-948.e8
Hatfield, M Jason; Binder, Randall J; Gannon, Rowan et al. (2018) Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza (""Danshen""). J Nat Prod 81:2410-2418
Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733
Drummond, Catherine J; Hanna, Jason A; Garcia, Matthew R et al. (2018) Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell 33:108-124.e5
Jones, Conor M; Baker, Justin N; Keesey, Rachel M et al. (2018) Importance ratings on patient-reported outcome items for survivorship care: comparison between pediatric cancer survivors, parents, and clinicians. Qual Life Res 27:1877-1884
Huang, I-Chan; Brinkman, Tara M; Mullins, Larry et al. (2018) Child symptoms, parent behaviors, and family strain in long-term survivors of childhood acute lymphoblastic leukemia. Psychooncology 27:2031-2038
Huang, I-Chan; Klosky, James L; Young, Chelsea M et al. (2018) Misclassification of self-reported smoking in adult survivors of childhood cancer. Pediatr Blood Cancer 65:e27240
Mandrell, Belinda N; Avent, Yvonne; Walker, Breya et al. (2018) In-home salivary melatonin collection: Methodology for children and adolescents. Dev Psychobiol 60:118-122

Showing the most recent 10 out of 6764 publications